Cirrhosis Reversal: The Sprint is Not Over Yet!

About the Speaker

Dr. Bansal is currently Professor of Medicine, Director of the newly formed NASH Center of Excellence, and Director of Translational Research in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai. Just recently she served as Secretary for AASLD, Deputy Chief Medical Officer for Mount Sinai Health Partners, and Vice President, Population Health for Quality and Efficiency. Dr. Bansal attended Harvard University and then Cornell Medical School. She did her internship and residency at Cornell Medical School and then completed Gastroenterology Fellowship at the University of Pennsylvania in 2001. Dr. Bansal joined the faculty at Mount Sinai in 2001 and from 2002-2009 she served as Transplant Hepatology Fellowship Director, leading one of the largest transplant hepatology fellowships in the United States. While remaining clinically active, she developed an NIH-funded basic research program focusing on understanding underlying molecular mechanisms of liver fibrosis and stellate cell biology in an effort to develop novel anti-fibrotic therapies. Her current research interests focus on the impact of HIV on hepatic inflammation and fibrosis and translational and clinical research in NASH. She has been the principal investigator for numerous clinical trials ranging from HCV to NASH. Over the past 5 years, her focus had also been on building a population health infrastructure that will allow a large academic health system to be successful in value-based care. She recently stepped down from this role to lead the NASH Center of Excellence at the Icahn School of Medicine developing a longitudinal registry, implementing screening and predictive algorithms for the identification of patients with significant fibrosis, creating multidisciplinary clinics, and conducting an array of investigator-initiated NASH translational and clinical studies.